BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Full-Time Employees (ESG Performance Table) by Year
BeOne Medicines Full-Time Employees (ESG Performance Table): 11,738 in FY2025, up 6.6% from a year earlier.
Latest, FY2025
11,738
Period ended Dec 31, 2025
Change on a year earlier
+6.6%
11,013 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Full-Time Employees Number 10,452 11,013 11,738”
Source: 2025 ESG Report ↗
Reported in BeOne Responsible Business & Sustainability Report (ESG).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Full-Time Employees (ESG Performance Table) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11,738 | +6.6% | 2025 ESG Report ↗ |
| FY2024 | Dec 31, 2024 | 11,013 | +5.4% | 2025 ESG Report ↗ |
| FY2023 | Dec 31, 2023 | 10,452 | +13.6% | 2025 ESG Report ↗ |
| FY2022 | Dec 31, 2022 | 9,201 | – | 2024 ESG Report ↗ |
Cite this data
StockData. (2026). BeOne Medicines Full-Time Employees (ESG Performance Table), annual FY2022–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/esg-emp-ft
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.